Archive2018

Swimming inhibits autoimmunity

Is swimming beneficial in MS? As part of our remit the UK government wants us to discuss animal experiments, and as this is a blog about good and bad research news, we will defend animal experimentation when it is useful. However, I think we need to be bold and say “Not in my name” when it is not.  Yes this goes against the norm on science reporting where “every thing is...

Why do I have MS?.. Because you have a common virus?

Deeba E, Koptides D, Gaglia E, Constantinou A, Lambrianides A, Pantzaris M, Krashias G, Christodoulou C. Evaluation of Epstein-Barr virus-specific antibodies in Cypriot multiple sclerosis patients. Mol Immunol. 2018;105:270-275 Multiple Sclerosis (MS) is a chronic, demyelinating, inflammatory disease of the central nervous system (CNS) with a strong autoimmune component. Several genetic and...

Measuring astrocyte function for a blood test

Högel H, Rissanen E, Barro C, Matilainen M, Nylund M, Kuhle J, Airas L.Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Mult Scler. 2018 Dec 20:1352458518819380. BACKGROUND:Cerebrospinal fluid (CSF) levels of two soluble biomarkers, glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL), have been shown to associate with multiple...

Turning off oligodendrocytes a switch for myelination

How do we make an active oligodendroctye Jing Wang, Darpan, Anjali K. Sinha, Jessie Polanco, Karen Dietz, Melanie A. O’Bara, Suyog U. Pol, Hani J. Shayya, and Fraser J. Sim C December 18 2018.doi:10.1016/j.celrep.2018.11.068 Human oligodendrocyte progenitor cells (hOPCs) persist into adulthood as an abundant precursor population capable of division and differentiation. The transcriptional...

The end of gadolinium use in MS imaging

Merry Christmas everyone, and Happy holidays 😊 Whilst, writing today’s blog post I find myself fortunate to be able to look back and say MS has come leaps and bounds over the last ten years, and looking ahead we stand at the cusp of an increasing number of clinical trials targeting progressive MS. Scientists and doctors have worked hard to improve the sensitivity of our diagnostic...

Asthma and MS

This study suggests that asthma occurrence is higher than MS Hill E, Abboud H, Briggs FBS.Prevalence of asthma in multiple sclerosis: A United States population-based study.Mult Scler Relat Disord. 2018 Dec 12;28:69-74 BACKGROUND:Multiple sclerosis (MS) and asthma are complex multifactorial diseases which adversely impact daily functioning. However, the prevalence of asthma in those with MS...

Astrocytes at the centre of lymphocyte recruitment?

Genetics on the outside-in/Inside out trail of immune activation in MS. Evidence for the astrocyte Ponath G, Lincoln MR, Levine-Ritterman M, Park C, Dahlawi S, Mubarak M, Sumida T, Airas L, Zhang S, Isitan C, Nguyen TD, Raine CS, Hafler DA, Pitt D. Enhanced astrocyte responses are driven by a genetic risk allele associated with multiple sclerosis.Nat Commun. 2018 Dec 17;9(1):5337...

More T cells stuff, is the B cell idea wrong?

If MS is a T cell mediated disease how does ocrelizumab (CD20 B cell depleting antibody) work Simple because T cells express CD20 Is this a blow for the B cell idea? von Essen MR, Ammitzbøll C, Hansen RH, Petersen ERS, McWilliam O, Marquart HV, Damm P, Sellebjerg F. Pro-inflammatory CD20+ T cells in the pathogenesis of multiple sclerosis. Brain. 2018 Dec 17. doi: 10.1093/brain/awy301...

Can Alemtuzumab reduce CSF neurofilaments? A Barts MS Study

Amongst the heavy hitters that includes fingolimod, alemtuzumab, natalizumab and ocrelizumab, the ultimate measure of treatment effectiveness is their ability to protect brain volume loss. The release of axonal proteins, including neurofilaments, have been demonstrated to closely emulate this slow brain volume loss that we see in MS (Figure 1).  Figure 1: Scatterplots showing...

Cost effectiveness of DMT , guess who wins

I’ve been taken to task about talking about autoimmunities and not singing the praise of alemtuzumab. I can only present stuff thats published, so if it doesnt see the light of day it is hard to talk anything. So to break the mould Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in...

Translate

Categories

Recent Posts

Recent Comments

Archives